Franco-de la Torre Lorenzo, Gómez-Sánchez Eduardo, Aragon-Martinez Othoniel Hugo, Hernández-Gómez Adriana, Franco-González Diana Laura, Guzmán-Flores Juan Manuel, Alonso-Castro Angel Josabad, Granados-Soto Vinicio, Isiordia-Espinoza Mario Alberto
Instituto de Investigación en Ciencias Médicas, Cuerpo Académico Terapéutica y Biología Molecular (UDG-CA-973), Departamento de Clínicas, División de Ciencias Biomédicas, Centro Universitario de los Altos, Universidad de Guadalajara, Tepatitlán de Morelos 47620, Mexico.
División de Disciplinas Clínicas, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Mexico.
Pharmaceuticals (Basel). 2023 Sep 12;16(9):1287. doi: 10.3390/ph16091287.
The aim of this systematic review and meta-analysis was to evaluate the analgesic effect of different doses of tapentadol immediate release (IR) and its adverse effects after a bunionectomy. Pubmed, Cochrane, Lilacs, Medline, and Imbiomed were used to identify abstracts of scientific publications related to the keywords of this systematic review (PROSPERO ID CRD42023437295). Moreover, the risk of bias in all included articles was assessed using the Cochrane Collaboration risk of bias tool. Data on the sum of pain intensity, total pain relief, global assessment, and adverse effects were extracted. The statistical method of inverse variance with means difference was used to evaluate the numerical data and the Mantel-Haenszel and Odd Ratio test to analyze the dichotomous data. In addition, the number needed to treat, the number needed to harm, and the 95% confidence intervals were calculated. A qualitative evaluation ( = 2381) was carried out according to the conclusions of the authors. Tapentadol ( = 1772) was more effective in relieving postoperative pain than the placebo ( = 609) after a bunionectomy. In addition, the analgesic efficacy of IR tapentadol ( = 1323) versus the placebo ( = 390) was evaluated in a total of 1713 patients using a global evaluation of the treatments. All three doses of IR tapentadol showed better results compared to the placebo after a bunionectomy. Finally, the adverse effects have a direct relationship with the dose, and the greatest number of adverse effects are most observed with tapentadol IR 100 mg ( = 2381). It is concluded that tapentadol IR (100 mg) leads to the best satisfaction score in this meta-analysis.
本系统评价和荟萃分析的目的是评估不同剂量的速释曲马多在拇外翻切除术后的镇痛效果及其不良反应。使用PubMed、Cochrane、Lilacs、Medline和Imbiomed来识别与本系统评价关键词相关的科学出版物摘要（PROSPERO编号CRD42023437295）。此外，使用Cochrane协作偏倚风险工具评估所有纳入文章的偏倚风险。提取疼痛强度总和、总疼痛缓解、整体评估和不良反应的数据。采用均值差的逆方差统计方法评估数值数据，采用Mantel - Haenszel和比值比检验分析二分数据。此外，计算治疗所需人数、伤害所需人数和95%置信区间。根据作者的结论进行了定性评价（= 2381）。在拇外翻切除术后，曲马多（= 1772）比安慰剂（= 609）更有效地缓解术后疼痛。此外，在总共1713名患者中，使用对治疗的整体评估来评估速释曲马多（= 1323）与安慰剂（= 390）的镇痛效果。与安慰剂相比，所有三种剂量的速释曲马多在拇外翻切除术后均显示出更好的效果。最后，不良反应与剂量有直接关系，在100 mg速释曲马多中观察到的不良反应数量最多（= 2381）。得出的结论是，在本荟萃分析中，100 mg速释曲马多导致最佳满意度评分。
